Experienced in Autoimmune Hemolytic Anemia

Dr. Neelima Denduluri

Hematology Oncology
1635 N George Mason Dr, Ste 170, 
Arlington, VA 
Accepting New Patients
Experienced in Autoimmune Hemolytic Anemia
1635 N George Mason Dr, Ste 170, 
Arlington, VA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Neelima Denduluri is a Hematologist Oncology provider in Arlington, Virginia. Dr. Denduluri is rated as an Experienced provider by MediFind in the treatment of Autoimmune Hemolytic Anemia. Her top areas of expertise are Breast Cancer, Paget Disease of the Breast, Pleuropulmonary Blastoma, and HER2 Negative Breast Cancer. Dr. Denduluri is currently accepting new patients.

Her clinical research consists of co-authoring 46 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Licenses
Internal Medicine in DC
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Piedmont
  • HMO
  • POS

Locations

1635 N George Mason Dr, Ste 170, Arlington, VA 22205

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Single Arm, Open Label Phase 2 Study of Tucatinib in Combination With Trastuzumab Deruxtecan in Subjects With Previously Treated Unresectable Locally-Advanced or Metastatic HER2+ Breast Cancer
A Single Arm, Open Label Phase 2 Study of Tucatinib in Combination With Trastuzumab Deruxtecan in Subjects With Previously Treated Unresectable Locally-Advanced or Metastatic HER2+ Breast Cancer
Enrollment Status: Completed
Publish Date: September 30, 2025
Intervention Type: Drug
Study Drugs: tucatinib, trastuzumab deruxtecan
Study Phase: Phase 2
Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Subjects With Unresectable Locally-advanced or Metastatic HER2+ Breast Cancer (HER2CLIMB-02)
Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Subjects With Unresectable Locally-advanced or Metastatic HER2+ Breast Cancer (HER2CLIMB-02)
Enrollment Status: Active_not_recruiting
Publish Date: August 07, 2025
Intervention Type: Drug
Study Drugs: tucatinib, T-DM1
Study Phase: Phase 3
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3
A Phase III Randomized Double-blind, Placebo Controlled Study of Alpelisib in Combination With Fulvestrant for Men and Postmenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment
A Phase III Randomized Double-blind, Placebo Controlled Study of Alpelisib in Combination With Fulvestrant for Men and Postmenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment
Enrollment Status: Completed
Publish Date: February 13, 2025
Intervention Type: Drug
Study Drugs: Fulvestrant, Alpelisib
Study Phase: Phase 3
A Phase III Multi-center, Randomized, Open-label Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as an Adjuvant Treatment in Patients With Hormone Receptor-positive, HER2-negative Early Breast Cancer (New Adjuvant TriAl With Ribociclib [LEE011]: NATALEE)
A Phase III Multi-center, Randomized, Open-label Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as an Adjuvant Treatment in Patients With Hormone Receptor-positive, HER2-negative Early Breast Cancer (New Adjuvant TriAl With Ribociclib [LEE011]: NATALEE)
Enrollment Status: Active_not_recruiting
Publish Date: November 14, 2024
Intervention Type: Drug, Other
Study Drug: Ribociclib
Study Phase: Phase 3
A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Breast or Gynecologic Malignancies
A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Breast or Gynecologic Malignancies
Enrollment Status: Completed
Publish Date: May 24, 2024
Intervention Type: Drug
Study Drugs: Etrumadenant, IPI-549, Pegylated liposomal doxorubicin, Nab-paclitaxel
Study Phase: Phase 1
A Phase II, Multicenter, Open Label Study of Bintrafusp Alfa (M7824) Monotherapy in Participants With HMGA2-expressing Triple Negative Breast Cancer
A Phase II, Multicenter, Open Label Study of Bintrafusp Alfa (M7824) Monotherapy in Participants With HMGA2-expressing Triple Negative Breast Cancer
Enrollment Status: Terminated
Publish Date: April 10, 2023
Intervention Type: Drug
Study Drug: Bintrafusp alfa
Study Phase: Phase 2
An Open Label, Multi-center Protocol for U.S. Patients Enrolled in a Study of Ribociclib With Endocrine Therapy as an Adjuvant Treatment in Patients With Hormone Receptor-positive, HER2-negative, High Risk Early Breast Cancer
An Open Label, Multi-center Protocol for U.S. Patients Enrolled in a Study of Ribociclib With Endocrine Therapy as an Adjuvant Treatment in Patients With Hormone Receptor-positive, HER2-negative, High Risk Early Breast Cancer
Enrollment Status: Completed
Publish Date: October 11, 2021
Intervention Type: Drug
Study Phase: Phase 2
Utilizing Multiomic Advanced Diagnostics to Identify CDK 4/6 Inhibitor Response Predictors and a Post-treatment Multiomic Signature for Patients With ER+/HER2- Metastatic Breast Cancer
Utilizing Multiomic Advanced Diagnostics to Identify CDK 4/6 Inhibitor Response Predictors and a Post-treatment Multiomic Signature for Patients With ER+/HER2- Metastatic Breast Cancer
Enrollment Status: Completed
Publish Date: July 01, 2020
Intervention Type: Other
Study Phase: Not Applicable
View 8 Less Clinical Trials

46 Total Publications

The impact of coadministration of venlafaxine, citalopram or gabapentin on the metabolic activation of tamoxifen.
The impact of coadministration of venlafaxine, citalopram or gabapentin on the metabolic activation of tamoxifen.
Journal: Breast cancer research and treatment
Published: December 02, 2024
Similar Doctors
Advanced in Autoimmune Hemolytic Anemia
Dr. Bruce R. Kressel
Hematology Oncology | Hematology | Oncology
Advanced in Autoimmune Hemolytic Anemia
Dr. Bruce R. Kressel
Hematology Oncology | Hematology | Oncology

Johns Hopkins University

8600 Old Georgetown Rd, 
Bethesda, MD 
 (7.5 miles away)
301-896-3100
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Bruce Kressel is a Hematologist Oncology specialist and a Hematologist in Bethesda, Maryland. Dr. Kressel is rated as a Distinguished provider by MediFind in the treatment of Autoimmune Hemolytic Anemia. His top areas of expertise are Essential Thrombocythemia, Non-Hodgkin Lymphoma, Gastric Lymphoma, Chronic Lymphocytic Leukemia (CLL), and Splenectomy.

Distinguished in Autoimmune Hemolytic Anemia
Dr. Elhamy D. Eskander
Oncology | Hematology | Hematology Oncology
Distinguished in Autoimmune Hemolytic Anemia
Dr. Elhamy D. Eskander
Oncology | Hematology | Hematology Oncology

Frederick Health Medical Group LLC

194 Thomas Johnson Dr, 
Frederick, MD 
 (41.4 miles away)
240-215-6310
Languages Spoken:
English
See accepted insurances

Elhamy Eskander is an Oncologist and a Hematologist in Frederick, Maryland. Dr. Eskander is rated as a Distinguished provider by MediFind in the treatment of Autoimmune Hemolytic Anemia. His top areas of expertise are Lung Cancer, Childhood Iron Deficiency Anemia, Pleuropulmonary Blastoma, and Autoimmune Hemolytic Anemia.

Advanced in Autoimmune Hemolytic Anemia
Dr. Kenneth L. Abbott
Hematology Oncology | Oncology | Hematology
Advanced in Autoimmune Hemolytic Anemia
Dr. Kenneth L. Abbott
Hematology Oncology | Oncology | Hematology

Calverthealth Medical Group, LLC

110 Hospital Rd, Suite 105, 
Prince Frederick, MD 
 (36.5 miles away)
410-414-9116
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Kenneth Abbott is a Hematologist Oncology specialist and an Oncologist in Prince Frederick, Maryland. Dr. Abbott is rated as a Distinguished provider by MediFind in the treatment of Autoimmune Hemolytic Anemia. His top areas of expertise are Neuroendocrine Carcinoma of the Cervix, Cervical Cancer, Familial Colorectal Cancer, and Ovarian Carcinosarcoma. Dr. Abbott is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Denduluri's expertise for a condition
ConditionClose
View All 21 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile